跳转至内容
Merck
CN

P7306

聚乙二醇/二甲基亚砜溶液

Hybri-Max, average mol wt 1,450, 50 % (w/v), 0.2 μm filtered, BioReagent, suitable for hybridoma

别名:

PEG/DMSO溶液, PEG和DMSO溶液, 聚乙二醇溶液

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

MDL number:
UNSPSC Code:
12161902
PubChem Substance ID:
NACRES:
NA.75
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

Hybri-Max

Quality Level

sterility

0.2 μm filtered

product line

BioReagent

form

solution

mol wt

average mol wt 1,450

concentration

50 % (w/v)

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

storage temp.

2-8°C

SMILES string

C(CO)O

InChI

1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2

InChI key

LYCAIKOWRPUZTN-UHFFFAOYSA-N

Application

PEG在单克隆抗体生产中用作杂交瘤制备的细胞融合剂,诱导细胞杂交。


推荐用于要求50%聚乙二醇和10%二甲基亚砜的正常融合方案。

Packaging

在氮气氛围下密封在安瓿瓶中。

Preparation Note

溶液随时可用。如果需要浓度较低的溶液,用无菌无钙DPBS稀释(D5773)。一些沉淀物在暴露于较冷的环境后可能会出现,但随着溶液变暖,这些沉淀物会消失。如果需要,溶液可以冷冻,但首先应等分,以避免重复冷冻/解冻循环。

Other Notes

含有50% (w/v)聚乙二醇(平均摩尔重量1450)和不含钙的10%二甲基亚砜(体积比)。

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC


存储类别

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Wen-Hung Chen et al.
Virology journal, 14(1), 189-189 (2017-10-04)
Dengue virus (DV) infection causes a spectrum of clinical diseases ranging from dengue fever to a life-threatening dengue hemorrhagic fever. Four distinct serotypes (DV1-4), which have similar genome sequences and envelope protein (E protein) antigenic properties, were divided. Among these
Indre Kucinskaite-Kodze et al.
Biomolecules, 10(7) (2020-07-12)
The pathogenicity of many bacteria, including Streptococcus pneumoniae, depends on pore-forming toxins (PFTs) that cause host cell lysis by forming large pores in cholesterol-containing cell membranes. Therefore, PFTs-neutralising antibodies may provide useful tools for reducing S. pneumoniae pathogenic effects. This
Shudan Wang et al.
Theranostics, 10(15), 6854-6874 (2020-06-20)
Repeated failures of "Aβ-lowering" therapies call for new targets and therapeutic approaches for Alzheimer's disease (AD). We propose to treat AD by halting neuronal death and repairing synapses using a BDNF-based therapy. To overcome the poor druggability of BDNF, we



全球贸易项目编号

货号GTIN
P7306-5X5ML04061834394600